Cardinal Health extends CVS Health distribution deal to 2032

The extension replaces an agreement that was due to run out in 2027 and comes with reaffirmed earnings guidance.

Cardinal Health has signed a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 30, 2032. The current agreement had been set to expire in June 2027.

Cardinal Health CEO Jason Hollar said the company looks forward to continuing to bring its capabilities together to serve CVS Health's customers.

The two companies have extended the arrangement before. A three-year extension was announced in December 2013, and the agreement was extended again in August 2021 through June 2027, according to Cardinal Health's regulatory filings. CVS Health accounted for 25% of Cardinal Health's revenue in fiscal 2022 and 26% in each of the two years before that, the filings show. Cardinal Health's announcement of the new agreement describes it as a continuation of the current scope of distribution services, without detailing changes to pricing, volume or exclusivity.

Alongside the extension, Cardinal Health reaffirmed its fiscal 2027 non-GAAP earnings guidance of $12.40 to $12.60 a share and its long-term non-GAAP earnings growth target of 12% to 14%. Extending the contract five years beyond its prior expiry removes a renewal question that recurs periodically in pharmaceutical distribution, giving both companies more visibility on revenue and supply than a shorter rollover would. Pairing that extension with reaffirmed guidance signals that management does not expect the renewed terms to disrupt margins or volume. For a wholesaler whose business runs on high-volume, low-margin logistics, a contract of this size is a core driver of how predictable its earnings are, and locking in the relationship this far out reduces the risk of renegotiating on worse terms later in the decade.